Business Context and Reporting Period
This Form 8-K is a current report filed by Pieris Pharmaceuticals, Inc. (PIRS) on June 29, 2020, regarding events occurring at the Annual Meeting of Stockholders held on June 23, 2020. The filing details the outcomes of shareholder votes and the approval of corporate governance matters.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for any financial metric.
Material Changes and Corporate Actions
- Equity Plan Approval: Stockholders approved the 2020 Employee, Director and Consultant Equity Incentive Plan (2020 EIP), which became effective immediately upon approval.
- Director Elections: Stephen S. Yoder, Michael Richman, and Matthew L. Sherman, M.D. were elected as Class III directors for three-year terms expiring in 2023.
- Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
- Executive Compensation: Stockholders approved the "Say on Pay" proposal and voted for an annual frequency for future Say on Pay votes.
Voting Results Summary
| Proposal | Votes For | Votes Against/Withheld | Abstentions |
|---|---|---|---|
| Election of Directors (Class III) | Varied by candidate (approx. 15.9M - 17.0M) | Varied by candidate (approx. 2.7M - 3.8M) | N/A |
| 2020 EIP Approval | 19,072,745 | 597,972 | 51,138 |
| Auditor Ratification | 33,215,900 | 218,365 | 42,854 |
| Say on Pay | 19,240,537 | 357,178 | 124,140 |
| Say on Pay Frequency (1 Year) | 18,973,582 | N/A | 107,579 |
Quorum: 33,477,119 shares (63.98% of outstanding shares) were present in person or by proxy.
Guidance, Outlook, and Risks
This filing does not contain management guidance, financial outlook, risk factors, or discussion of contingencies. It strictly reports on the administrative outcomes of the Annual Meeting.
Investor Verification Checklist
- Verify the specific terms of the 2020 Equity Incentive Plan by reviewing Exhibit 10.1 referenced in the filing.
- Confirm the share count eligible to vote (52,320,635) against the company's most recent 10-Q or 10-K to ensure no subsequent dilution or buybacks have occurred.
- Review the Proxy Statement (Schedule 14A) filed on April 28, 2020, for detailed biographies of the newly elected directors and full compensation details.
- Note that 13,755,264 shares were broker non-votes on several proposals, indicating a significant portion of shares held in street name did not receive voting instructions.